Publications from Clinical Cancer Research Unit (CRU)

Publications 2018

Bjørnelv GMW, Dueland S, Line PD, Joranger P, Fretland ÅA, Edwin B, Sørbye H, Aas E (2018)
Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver
Br J Surg (in press)
DOI 10.1002/bjs.10962, PubMed 30325494

Bousquet PA, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH (2018)
Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer
Transl Oncol, 12 (1), 76-83 (in press)
DOI 10.1016/j.tranon.2018.09.010, PubMed 30273860

Boysen AK, Sørensen BS, Lefevre AC, Abrantes R, Johansen JS, Jensen BV, Schou JV, Larsen FO, Nielsen D, Taflin H, Gustavson B, Wettergren Y, Sorensen BS, Ree AH, Dueland S, Pallisgaard N, Spindler KL (2018)
Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer
Clin Chim Acta, 487, 107-111 (in press)
DOI 10.1016/j.cca.2018.09.029, PubMed 30240586

Dueland S, Foss A, Solheim JM, Hagness M, Line PD (2018)
Survival following liver transplantation for liver-only colorectal metastases compared with hepatocellular carcinoma
Br J Surg, 105 (6), 736-742
DOI 10.1002/bjs.10769, PubMed 29532908

Grut H, Revheim ME, Line PD, Dueland S (2018)
Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation
Nucl Med Commun, 39 (7), 621-627
DOI 10.1097/MNM.0000000000000843, PubMed 29683930

Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH (2018)
Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
Br J Cancer, 118 (10), 1322-1328
DOI 10.1038/s41416-018-0085-y, PubMed 29695770

Line PD, Hagness M, Dueland S (2018)
The Potential Role of Liver Transplantation as a Treatment Option in Colorectal Liver Metastases
Can J Gastroenterol Hepatol, 2018, 8547940
DOI 10.1155/2018/8547940, PubMed 29623266

Mariathasan AB, Boye K, Giercksky KE, Brennhovd B, Gullestad HP, Emblemsvåg HL, Grøholt KK, Dueland S, Flatmark K, Larsen SG (2018)
Beyond total mesorectal excision in locally advanced rectal cancer with organ or pelvic side-wall involvement
Eur J Surg Oncol, 44 (8), 1226-1232
DOI 10.1016/j.ejso.2018.03.029, PubMed 29691115

Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S, Gelderblom H, Italiano A, Lindner LH, Hennig I, Strauss S, Zakotnik B, Anthoney A, Albiges L, Blay JY, Reichardt P, Sufliarsky J, van der Graaf WTA, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Raveloarivahy T, Collette S et al. (2018)
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'
Ann Oncol, 29 (3), 758-765
DOI 10.1093/annonc/mdx774, PubMed 29216400

Schöffski P, Wozniak A, Leahy MG, Aamdal S, Rutkowski P, Bauer S, Richter S, Grünwald V, Debiec-Rychter M, Sciot R, Geoerger B, Marréaud S, Collette S, Nzokirantevye A, Strauss SJ (2018)
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'
Eur J Cancer, 94, 156-167
DOI 10.1016/j.ejca.2018.02.011, PubMed 29567632

Smedman TM, Line PD, Guren TK, Dueland S (2018)
Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients
Acta Oncol, 57 (10), 1414-1418
DOI 10.1080/0284186X.2018.1479069, PubMed 29912605

Valan CD, Slagsvold JE, Halvorsen TO, Herje M, Bremnes RM, Brunsvig PF, Brustugun OT, Fløtten Ø, Levin N, Sundstrøm SH, Grønberg BH (2018)
Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement
Anticancer Res, 38 (2), 871-876
DOI 10.21873/anticanres.12296, PubMed 29374714

Publications 2017

Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR (2017)
Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival
Acta Oncol, 56 (6), 813-818
DOI 10.1080/0284186X.2017.1287951, PubMed 28464745

Dueland S, Guren TK, Boberg KM, Reims HM, Grzyb K, Aamdal S, Julsrud L, Line PD (2017)
Acute liver graft rejection after ipilimumab therapy
Ann Oncol, 28 (10), 2619-2620
DOI 10.1093/annonc/mdx281, PubMed 28961840

Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim SW, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim DW, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB (2017)
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer
J Thorac Oncol, 13 (4), 576-584
DOI 10.1016/j.jtho.2017.11.131, PubMed 29247830

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Olsen KH, Giercksky KE, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2017)
Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial
Ann Surg Oncol, 24 (7), 1916-1922
DOI 10.1245/s10434-017-5814-6, PubMed 28224367

Grut H, Dueland S, Line PD, Revheim ME (2017)
The prognostic value of 18F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases
Eur J Nucl Med Mol Imaging, 45 (2), 218-225
DOI 10.1007/s00259-017-3843-9, PubMed 29026950

Grut H, Solberg S, Seierstad T, Revheim ME, Egge TS, Larsen SG, Line PD, Dueland S (2017)
Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases
Br J Surg, 105 (3), 295-301
DOI 10.1002/bjs.10651, PubMed 29168565

Labori KJ, Guren MG, Brudvik KW, Røsok BI, Waage A, Nesbakken A, Larsen S, Dueland S, Edwin B, Bjørnbeth BA (2017)
Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short-term surgical outcomes, overall survival and recurrence-free survival
Colorectal Dis, 19 (8), 731-738
DOI 10.1111/codi.13622, PubMed 28181384

Labori KJ, Lassen K, Hoem D, Grønbech JE, Søreide JA, Mortensen K, Smaaland R, Sorbye H, Verbeke C, Dueland S (2017)
Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial
BMC Surg, 17 (1), 94
DOI 10.1186/s12893-017-0291-1, PubMed 28841916

Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM (2017)
Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer
Cancer Immunol Immunother, 66 (7), 891-901
DOI 10.1007/s00262-017-1994-y, PubMed 28391357

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742

Van Laethem JL, Riess H, Jassem J, Haas M, Martens UM, Weekes C, Peeters M, Ross P, Bridgewater J, Melichar B, Cascinu S, Saramak P, Michl P, Van Brummelen D, Zaniboni A, Schmiegel W, Dueland S, Giurescu M, Garosi VL, Roth K, Schulz A, Seidel H, Rajagopalan P, Teufel M, Childs BH (2017)
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
Target Oncol, 12 (1), 97-109
DOI 10.1007/s11523-016-0469-y, PubMed 27975152

Publications 2016

Ardizzoni A, Tiseo M, Boni L, Di Maio M, Buffoni L, Belvedere O, Grossi F, D'Alessandro V, de Marinis F, Barbera S, Caroti C, Favaretto A, Cortinovis D, Morrica B, Tixi L, Ceschia T, Parisi S, Ricardi U, Grimaldi A, Loreggian L, Navarria P, Huber RM, Belani C, Brunsvig PF, Scagliotti GV et al. (2016)
Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC
Lung Cancer, 100, 30-37
DOI 10.1016/j.lungcan.2016.07.026, PubMed 27597278

Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K (2016)
Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome
Clin Oncol (R Coll Radiol), 28 (8), 532-9
DOI 10.1016/j.clon.2016.01.014, PubMed 26888115

Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH (2016)
Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
Radiother Oncol, 119 (3), 505-11
DOI 10.1016/j.radonc.2016.02.020, PubMed 26968754

Frøysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K (2016)
Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort
J Surg Oncol, 114 (2), 222-7
DOI 10.1002/jso.24290, PubMed 27173150

Halvorsen TO, Sundstrøm S, Fløtten Ø, Brustugun OT, Brunsvig P, Aasebø U, Bremnes RM, Kaasa S, Grønberg BH (2016)
Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer
Acta Oncol, 55 (11), 1349-1354
DOI 10.1080/0284186X.2016.1201216, PubMed 27549509

Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH (2016)
Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening
BMC Cancer, 16, 536
DOI 10.1186/s12885-016-2601-x, PubMed 27461255

Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH (2016)
Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy
Cancer Res Treat, 49 (2), 374-386
DOI 10.4143/crt.2016.080, PubMed 27488871

Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M (2016)
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
Oncoimmunology, 5 (12), e1249090
DOI 10.1080/2162402X.2016.1249090, PubMed 28123886

Kyte JA, Aamdal S, Dueland S, Sæbøe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G (2016)
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
Oncoimmunology, 5 (11), e1232237
DOI 10.1080/2162402X.2016.1232237, PubMed 27999747

Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH (2016)
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
Oncotarget, 7 (23), 34907-17
DOI 10.18632/oncotarget.8995, PubMed 27145458

Sioud M, Nyakas M, Sæbøe-Larssen S, Mobergslien A, Aamdal S, Kvalheim G (2016)
Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
Case Rep Med, 2016, 9639585
DOI 10.1155/2016/9639585, PubMed 27504122

Publications 2015

Andersson Y, Engebraaten O, Juell S, Aamdal S, Brunsvig P, Fodstad Ø, Dueland S (2015)
Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
Br J Cancer, 113 (11), 1548-55
DOI 10.1038/bjc.2015.380, PubMed 26554649

Carling U, Dorenberg EJ, Haugvik SP, Eide NA, Berntzen DT, Edwin B, Dueland S, Røsok B (2015)
Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications
Cardiovasc Intervent Radiol, 38 (6), 1532-41
DOI 10.1007/s00270-015-1093-4, PubMed 25832764

Dueland S, Guren TK, Hagness M, Glimelius B, Line PD, Pfeiffer P, Foss A, Tveit KM (2015)
Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer?
Ann Surg, 261 (5), 956-60
DOI 10.1097/SLA.0000000000000786, PubMed 24950280

Grønberg BH, Halvorsen TO, Fløtten Ø, Brustugun OT, Brunsvig PF, Aasebø U, Bremnes RM, Tollåli T, Hornslien K, Aksnessæther BY, Liaaen ED, Sundstrøm S, Norwegian Lung Cancer Study Group (2015)
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer
Acta Oncol, 55 (5), 591-7
DOI 10.3109/0284186X.2015.1092584, PubMed 26494411

Hansen GL, Gaudernack G, Brunsvig PF, Cvancarova M, Kyte JA (2015)
Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination
Cancer Immunol Immunother, 64 (12), 1609-21
DOI 10.1007/s00262-015-1766-5, PubMed 26498005

Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH (2015)
Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
BMC Cancer, 15, 543
DOI 10.1186/s12885-015-1557-6, PubMed 26205955

Labori KJ, Katz MH, Tzeng CW, Bjørnbeth BA, Cvancarova M, Edwin B, Kure EH, Eide TJ, Dueland S, Buanes T, Gladhaug IP (2015)
Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study
Acta Oncol, 55 (3), 265-77
DOI 10.3109/0284186X.2015.1068445, PubMed 26213211

Line PD, Hagness M, Berstad AE, Foss A, Dueland S (2015)
A Novel Concept for Partial Liver Transplantation in Nonresectable Colorectal Liver Metastases: The RAPID Concept
Ann Surg, 262 (1), e5-9
DOI 10.1097/SLA.0000000000001165, PubMed 25692361

Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD (2015)
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial
J Clin Oncol, 33 (10), 1191-6
DOI 10.1200/JCO.2014.56.6018, PubMed 25713437

Prasmickaite L, Berge G, Bettum IJ, Aamdal S, Hansson J, Bastholt L, Øijordsbakken M, Boye K, Mælandsmo GM (2015)
Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial
Cancer Immunol Immunother, 64 (6), 769-76
DOI 10.1007/s00262-015-1686-4, PubMed 25832001

Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T (2015)
High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer
Radiother Oncol, 118 (2), 393-8
DOI 10.1016/j.radonc.2015.11.031, PubMed 26705680

Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR (2015)
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies
Crit Rev Oncol Hematol, 95 (1), 114-24
DOI 10.1016/j.critrevonc.2015.01.003, PubMed 25624177

Seierstad T, Hole KH, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR (2015)
MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer
Br J Radiol, 88 (1051), 20150097
DOI 10.1259/bjr.20150097, PubMed 25899892

Venugopal B, Awada A, Evans TR, Dueland S, Hendlisz A, Rasch W, Hernes K, Hagen S, Aamdal S (2015)
A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours
Cancer Chemother Pharmacol, 76 (4), 785-92
DOI 10.1007/s00280-015-2846-0, PubMed 26289594

Publications 2014

Dueland S, Hagness M, Line PD, Guren TK, Tveit KM, Foss A (2014)
Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy?
Ann Surg Oncol, 22 (7), 2195-200
DOI 10.1245/s10434-014-4137-0, PubMed 25297902

Guren MG, Undseth C, Rekstad BL, Brændengen M, Dueland S, Spindler KL, Glynne-Jones R, Tveit KM (2014)
Reirradiation of locally recurrent rectal cancer: a systematic review
Radiother Oncol, 113 (2), 151-7
DOI 10.1016/j.radonc.2014.11.021, PubMed 25613395

Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E (2014)
Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks
Int J Mol Sci, 15 (12), 22835-56
DOI 10.3390/ijms151222835, PubMed 25501337

Ree AH, Saelen MG, Kalanxhi E, Østensen IH, Schee K, Røe K, Abrahamsen TW, Dueland S, Flatmark K (2014)
Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy
PLoS One, 9 (2), e89750
DOI 10.1371/journal.pone.0089750, PubMed 24587009

Raabe NK, Sundfør K, Hole KH, Djupvik LH, Larsen SG, Dueland S (2014)
[High-dose-rate brachytherapy in recurrent rectal cancer after conventional recurrence treatment]
Tidsskr Nor Laegeforen, 134 (20), 1929-30
DOI 10.4045/tidsskr.14.1162, PubMed 25350435

Vihinen P, Tervahartiala T, Sorsa T, Hansson J, Bastholt L, Aamdal S, Stierner U, Pyrhönen S, Syrjänen K, Lundin J, Hernberg M (2014)
Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels
Cancer Immunol Immunother, 64 (2), 173-80
DOI 10.1007/s00262-014-1620-1, PubMed 25319807

Publications 2013

Brandberg Y, Johansson H, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, Hansson J, Nordic Melanoma Cooperative Group (2013)
Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma
Acta Oncol, 52 (6), 1086-93
DOI 10.3109/0284186X.2013.789140, PubMed 23621752

Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I, Kurzrock R (2013)
A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies
Eur J Cancer, 49 (7), 1521-9
DOI 10.1016/j.ejca.2013.01.013, PubMed 23433846

del Campo AB, Kyte JA, Carretero J, Zinchencko S, Méndez R, González-Aseguinolaza G, Ruiz-Cabello F, Aamdal S, Gaudernack G, Garrido F, Aptsiauri N (2013)
Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
Int J Cancer, 134 (1), 102-13
DOI 10.1002/ijc.28338, PubMed 23784959

Eggermont AM, Suciu S, Rutkowski P, Marsden J, Santinami M, Corrie P, Aamdal S, Ascierto PA, Patel PM, Kruit WH, Bastholt L, Borgognoni L, Bernengo MG, Davidson N, Polders L, Praet M, Spatz A (2013)
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial
J Clin Oncol, 31 (30), 3831-7
DOI 10.1200/JCO.2012.47.9303, PubMed 24019551

Geisler J, Bachmann IM, Nyakas M, Helsing P, Fjøsne HE, Mæhle LO, Aamdal S, Eide NA, Svendsen HL, Straume O, Robsahm TE, Jacobsen KD, Akslen LA (2013)
Malignant melanoma--diagnosis, treatment and follow-up in Norway
Tidsskr Nor Laegeforen, 133 (20), 2154-9
DOI 10.4045/tidsskr.12.1416, PubMed 24172628

Hagness M, Foss A, Egge TS, Dueland S (2013)
Patterns of recurrence after liver transplantation for nonresectable liver metastases from colorectal cancer
Ann Surg Oncol, 21 (4), 1323-9
DOI 10.1245/s10434-013-3449-9, PubMed 24370906

Hagness M, Foss A, Line PD, Scholz T, Jørgensen PF, Fosby B, Boberg KM, Mathisen O, Gladhaug IP, Egge TS, Solberg S, Hausken J, Dueland S (2013)
Liver transplantation for nonresectable liver metastases from colorectal cancer
Ann Surg, 257 (5), 800-6
DOI 10.1097/SLA.0b013e3182823957, PubMed 23360920

Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA (2013)
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
Cancer Immunol Immunother, 62 (9), 1499-509
DOI 10.1007/s00262-013-1453-3, PubMed 23817721

Publications 2012

Andersen MH, Dueland S, Hagness M, Vidnes T, Finstad ED, Wahl AK, Foss A (2012)
Quality of life following liver transplantation in patients with liver metastases from colorectal carcinoma
Scand J Caring Sci, 26 (4), 713-9
DOI 10.1111/j.1471-6712.2012.00984.x, PubMed 22452269

Kaye S, Aamdal S, Jones R, Freyer G, Pujade-Lauraine E, de Vries EG, Barriuso J, Sandhu S, Tan DS, Hartog V, Kuenen B, Ruijter R, Kristensen GB, Nyakas M, Barrett S, Burke W, Pietersma D, Stuart M, Emeribe U, Boven E (2012)
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
Br J Cancer, 106 (11), 1728-34
DOI 10.1038/bjc.2012.158, PubMed 22531637

Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K (2012)
Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer
PLoS One, 7 (11), e50806
DOI 10.1371/journal.pone.0050806, PubMed 23226389

Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U (2012)
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study
Ann Oncol, 24 (1), 152-60
DOI 10.1093/annonc/mds276, PubMed 22967994

Sørensen O, Flatmark K, Reed W, Wiig JN, Dueland S, Giercksky KE, Larsen SG (2012)
Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei
Eur J Surg Oncol, 38 (10), 969-76
DOI 10.1016/j.ejso.2012.06.552, PubMed 22763244

Publications 2011

Brandberg Y, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, Hansson J (2011)
Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b
Eur J Cancer, 48 (13), 2012-9
DOI 10.1016/j.ejca.2011.11.019, PubMed 22196968

Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH (2011)
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
Radiat Oncol, 6, 33
DOI 10.1186/1748-717X-6-33, PubMed 21473790

Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S (2011)
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial
Clin Cancer Res, 17 (21), 6847-57
DOI 10.1158/1078-0432.CCR-11-1385, PubMed 21918169

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG et al. (2011)
Defining the critical hurdles in cancer immunotherapy
J Transl Med, 9, 214
DOI 10.1186/1479-5876-9-214, PubMed 22168571

Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gómez H, Bastholt L, Chasalow SD, Berman D (2011)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
J Transl Med, 9, 204
DOI 10.1186/1479-5876-9-204, PubMed 22123319

Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase H, Nordic Melanoma Cooperative Group (2011)
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial
Lancet Oncol, 12 (2), 144-52
DOI 10.1016/S1470-2045(10)70288-6, PubMed 21256809

Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S (2011)
Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients
Clin Cancer Res, 17 (13), 4568-80
DOI 10.1158/1078-0432.CCR-11-0184, PubMed 21586625

Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G (2011)
hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
Cancer Immunol Immunother, 60 (6), 809-18
DOI 10.1007/s00262-011-0991-9, PubMed 21365467

Wiig JN, Larsen SG, Dueland S, Flatmark K, Giercksky KE (2011)
Salvage surgery for locally recurrent rectal cancer: total mesorectal excision during the primary operation does not influence the outcome
Colorectal Dis, 13 (5), 506-11
DOI 10.1111/j.1463-1318.2010.02256.x, PubMed 20236148

Zwierzina H, Bergmann L, Fiebig H, Aamdal S, Schöffski P, Witthohn K, Lentzen H (2011)
The preclinical and clinical activity of aviscumine: a potential anticancer drug
Eur J Cancer, 47 (10), 1450-7
DOI 10.1016/j.ejca.2011.02.022, PubMed 21482461

Aamdal S (2011)
Current approaches to adjuvant therapy of melanoma
Eur J Cancer, 47 Suppl 3, S336-7
DOI 10.1016/S0959-8049(11)70193-9, PubMed 21944005

Publications 2010

Edvardsen H, Brunsvig PF, Solvang H, Tsalenko A, Andersen A, Syvanen AC, Yakhini Z, Børresen-Dale AL, Olsen H, Aamdal S, Kristensen VN (2010)
SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance
Pharmacogenomics J, 10 (6), 513-23
DOI 10.1038/tpj.2010.6, PubMed 20157331

Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH (2010)
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling
Int J Radiat Oncol Biol Phys, 78 (2), 555-62
DOI 10.1016/j.ijrobp.2010.04.036, PubMed 20675069

Foss A, Adam R, Dueland S (2010)
Liver transplantation for colorectal liver metastases: revisiting the concept
Transpl Int, 23 (7), 679-85
DOI 10.1111/j.1432-2277.2010.01097.x, PubMed 20477993

Haugen F, Norheim F, Lian H, Wensaas AJ, Dueland S, Berg O, Funderud A, Skålhegg BS, Raastad T, Drevon CA (2010)
IL-7 is expressed and secreted by human skeletal muscle cells
Am J Physiol Cell Physiol, 298 (4), C807-16
DOI 10.1152/ajpcell.00094.2009, PubMed 20089933

Prasmickaite L, Skrbo N, Høifødt HK, Suo Z, Engebråten O, Gullestad HP, Aamdal S, Fodstad Ø, Maelandsmo GM (2010)
Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells
Pigment Cell Melanoma Res, 23 (3), 449-51
DOI 10.1111/j.1755-148X.2010.00690.x, PubMed 20236249

Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K (2010)
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
Lancet Oncol, 11 (5), 459-64
DOI 10.1016/S1470-2045(10)70058-9, PubMed 20378407

Strand TE, Brunsvig PF, Johannessen DC, Sundstrøm S, Wang M, Hornslien K, Bremnes RM, Stensvold A, Garpestad O, Norstein J (2010)
Potentially curative radiotherapy for non-small-cell lung cancer in Norway: a population-based study of survival
Int J Radiat Oncol Biol Phys, 80 (1), 133-41
DOI 10.1016/j.ijrobp.2010.01.050, PubMed 20452137

Publications 2009

Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB (2009)
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer
J Clin Oncol, 27 (25), 4116-23
DOI 10.1200/JCO.2008.20.2515, PubMed 19636016

Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Salès F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM, EORTC Melanoma Group and the Nordic Melanoma Group (2009)
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon
J Natl Cancer Inst, 101 (12), 869-77
DOI 10.1093/jnci/djp132, PubMed 19509353

Dueland S, Aamdal S, Lind MJ, Thomas H, Sandvold ML, Gaullier JM, Rasch W (2009)
Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study
Acta Oncol, 48 (1), 137-45
DOI 10.1080/02841860802183620, PubMed 18607882

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S (2009)
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer
J Clin Oncol, 27 (19), 3217-24
DOI 10.1200/JCO.2008.20.9114, PubMed 19433683

Gunnes N, Seierstad TG, Aamdal S, Brunsvig PF, Jacobsen AB, Sundstrøm S, Aalen OO (2009)
Assessing quality of life in a randomized clinical trial: correcting for missing data
BMC Med Res Methodol, 9, 28
DOI 10.1186/1471-2288-9-28, PubMed 19405936

Publications 2008

Bruheim K, Svartberg J, Carlsen E, Dueland S, Haug E, Skovlund E, Tveit KM, Guren MG (2008)
Radiotherapy for rectal cancer is associated with reduced serum testosterone and increased FSH and LH
Int J Radiat Oncol Biol Phys, 70 (3), 722-7
DOI 10.1016/j.ijrobp.2007.10.043, PubMed 18262088

Brunsvig PF, Flatmark K, Aamdal S, Høifødt H, Le H, Jakobsen E, Sandstad B, Fodstad O (2008)
Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients
Lung Cancer, 61 (2), 170-6
DOI 10.1016/j.lungcan.2007.12.018, PubMed 18261824

Faye RS, Paus E, Maelandsmo GM, Berner A, Høifødt HK, Fodstad Ø, Aamdal S (2008)
S100B in bone marrow aspirates in healthy individuals and malignant melanoma patients
Melanoma Res, 18 (2), 134-40
DOI 10.1097/CMR.0b013e3282f623d9, PubMed 18337650

Grønberg BH, Bremnes RM, Aasebø U, Brunsvig P, Fløtten O, Amundsen T, von Plessen C, Wang M, Sundstrøm S, Norwegian Lung Cancer Study Group (2008)
A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer
Lung Cancer, 63 (1), 88-93
DOI 10.1016/j.lungcan.2008.04.003, PubMed 18538889

Helbekkmo N, Aasebø U, Sundstrøm SH, von Plessen C, Brunsvig PF, Bremnes RM, Norwegian Lung Cancer Study Group (2008)
Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy
Lung Cancer, 62 (2), 253-60
DOI 10.1016/j.lungcan.2008.03.003, PubMed 18417246

Helsing P, Nymoen DA, Ariansen S, Steine SJ, Maehle L, Aamdal S, Langmark F, Loeb M, Akslen LA, Molven A, Andresen PA (2008)
Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas
Genes Chromosomes Cancer, 47 (2), 175-84
DOI 10.1002/gcc.20518, PubMed 18023021

Larsen SG, Wiig JN, Emblemsvaag HL, Grøholt KK, Hole KH, Bentsen A, Dueland S, Vetrhus T, Giercksky KE (2008)
Extended total mesorectal excision in locally advanced rectal cancer (T4a) and the clinical role of MRI-evaluated neo-adjuvant downstaging
Colorectal Dis, 11 (7), 759-67
DOI 10.1111/j.1463-1318.2008.01649.x, PubMed 18662240

Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G, Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation (2008)
A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial
J Natl Cancer Inst, 100 (8), 533-41
DOI 10.1093/jnci/djn088, PubMed 18398095

Ree AH, Bratland A, Dueland S (2008)
[Molecular targeted therapy in colorectal cancer]
Tidsskr Nor Laegeforen, 128 (2), 190-3
PubMed 18202731

Publications 2007

Brunsvig PF, Andersen A, Aamdal S, Kristensen V, Olsen H (2007)
Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy
BMC Cancer, 7, 197
DOI 10.1186/1471-2407-7-197, PubMed 17956601

Helbekkmo N, Sundstrøm SH, Aasebø U, Brunsvig PF, von Plessen C, Hjelde HH, Garpestad OK, Bailey A, Bremnes RM, Norwegian Lung Cancer Study Group (2007)
Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
Br J Cancer, 97 (3), 283-9
DOI 10.1038/sj.bjc.6603869, PubMed 17595658

Hernberg M, Mattila PS, Rissanen M, Hansson J, Aamdal S, Bastholt L, von der Maase H, Schmidt H, Stierner U, Tarkkanen J (2007)
The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma
J Immunother, 30 (7), 773-9
DOI 10.1097/CJI.0b013e31814e0898, PubMed 17893569

Larsen SG, Wiig JN, Dueland S, Giercksky KE (2007)
Prognostic factors after preoperative irradiation and surgery for locally advanced rectal cancer
Eur J Surg Oncol, 34 (4), 410-7
DOI 10.1016/j.ejso.2007.05.012, PubMed 17614249

Wiig JN, Dueland S, Larsen S, Giercksky KE (2007)
[Treatment of locally recurrent rectal cancer]
Tidsskr Nor Laegeforen, 127 (23), 3097-101
PubMed 18049503

Wiig JN, Larsen SG, Dueland S, Giercksky KE (2007)
Preoperative irradiation and surgery for local recurrence of rectal and rectosigmoid cancer. Prognostic factors with regard to survival and further local recurrence
Colorectal Dis, 10 (1), 48-57
DOI 10.1111/j.1463-1318.2007.01398.x, PubMed 18028472

Publications 2006

Andersen A, Warren DJ, Brunsvig PF, Aamdal S, Kristensen GB, Olsen H (2006)
High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection
BMC Clin Pharmacol, 6, 2
DOI 10.1186/1472-6904-6-2, PubMed 16412237

Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Møller M, Eriksen JA, Gaudernack G (2006)
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer
Cancer Immunol Immunother, 55 (12), 1553-64
DOI 10.1007/s00262-006-0145-7, PubMed 16491401

Guren MG, Tobiassen LB, Trygg KU, Drevon CA, Dueland S (2006)
Dietary intake and nutritional indicators are transiently compromised during radiotherapy for rectal cancer
Eur J Clin Nutr, 60 (1), 113-9
DOI 10.1038/sj.ejcn.1602274, PubMed 16205744

Jacobsen KD, Fosså SD, Aamdal S (2006)
[Malignant melanoma--diagnosis and treatment]
Tidsskr Nor Laegeforen, 126 (23), 3094-7
PubMed 17160112

Kyte JA, Kvalheim G, Lislerud K, thor Straten P, Dueland S, Aamdal S, Gaudernack G (2006)
T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells
Cancer Immunol Immunother, 56 (5), 659-75
DOI 10.1007/s00262-006-0222-y, PubMed 16947019

Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, Gullestad HP, Ryder T, Lislerud K, Hammerstad H, Gaudernack G (2006)
Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
Cancer Gene Ther, 13 (10), 905-18
DOI 10.1038/sj.cgt.7700961, PubMed 16710345

Sundstrøm S, Bremnes RM, Brunsvig P, Aasebø U, Kaasa S, Norwegian Lung Cancer Study Group (2006)
Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy?
J Thorac Oncol, 1 (8), 816-24
PubMed 17409965

Warloe T, Aamdal S, Reith A, Bryne M (2006)
[Retraction of: Diagnostics and treatment of early stages of oral cancer]
Tidsskr Nor Laegeforen, 126 (17), 2287
PubMed 16967079

Publications 2005

Brunsvig PF, Hatlevoll R, Berg R, Lauvvang G, Owre K, Wang M, Aamdal S (2005)
Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: a phase I/II study with 5 years' follow-up
Lung Cancer, 50 (1), 97-105
DOI 10.1016/j.lungcan.2005.05.010, PubMed 16005105

Kyte JA, Kvalheim G, Aamdal S, Saebøe-Larssen S, Gaudernack G (2005)
Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination
Cancer Gene Ther, 12 (6), 579-91
DOI 10.1038/sj.cgt.7700837, PubMed 15818380

Millward MJ, Joshua A, Kefford R, Aamdal S, Thomson D, Hersey P, Toner G, Lynch K (2005)
Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma
Invest New Drugs, 23 (3), 253-6
DOI 10.1007/s10637-005-6734-z, PubMed 15868382

Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, Hammerstad H, Waehre H, Raabe N, Gaudernack G (2005)
Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
Br J Cancer, 93 (7), 749-56
DOI 10.1038/sj.bjc.6602761, PubMed 16136047

Sauer T, Guren MG, Noren T, Dueland S (2005)
Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?
Histopathology, 47 (6), 560-4
DOI 10.1111/j.1365-2559.2005.02252.x, PubMed 16324192

Smyth JF, Aamdal S, Awada A, Dittrich C, Caponigro F, Schöffski P, Gore M, Lesimple T, Djurasinovic N, Baron B, Ravic M, Fumoleau P, Punt CJ, EORTC New Drug Development and Melanoma Groups (2005)
Phase II study of E7070 in patients with metastatic melanoma
Ann Oncol, 16 (1), 158-61
DOI 10.1093/annonc/mdi016, PubMed 15598954

Sundstrøm S, Bremnes R, Brunsvig P, Aasebø U, Olbjørn K, Fayers PM, Kaasa S, Norwegian Lung Cancer Study Group (2005)
Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study
Radiother Oncol, 75 (2), 141-8
DOI 10.1016/j.radonc.2005.03.028, PubMed 16094739

Wiig JN, Larsen SG, Dueland S, Giercksky KE (2005)
Clinical outcome in patients with complete pathologic response (pT0) to preoperative irradiation/chemo-irradiation operated for locally advanced or locally recurrent rectal cancer
J Surg Oncol, 92 (1), 70-5
DOI 10.1002/jso.20340, PubMed 16180215

Publications 2004

Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y (2004)
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study
J Clin Oncol, 22 (6), 1118-25
DOI 10.1200/JCO.2004.04.165, PubMed 15020614

Bos AM, Boom K, Vinks AA, Boezen HM, Wanders J, Dombernovsky P, Aamdal S, de Vries EG, Uges DR (2004)
Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755
Cancer Chemother Pharmacol, 54 (1), 64-70
DOI 10.1007/s00280-004-0772-7, PubMed 15069581

Cheng JD, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt LR, Fernberg O, Schiller J, Forsberg G, Alpaugh RK, Weiner LM, Rogatko A (2004)
Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936
J Clin Oncol, 22 (4), 602-9
DOI 10.1200/JCO.2004.12.034, PubMed 14966084

Faye RS, Aamdal S, Høifødt HK, Jacobsen E, Holstad L, Skovlund E, Fodstad Ø (2004)
Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients
Clin Cancer Res, 10 (12 Pt 1), 4134-9
DOI 10.1158/1078-0432.CCR-03-0408, PubMed 15217950

Guren MG, Schneede J, Tveit KM, Ueland PM, Nexø E, Dueland S (2004)
Biochemical signs of impaired cobalamin status during and after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 60 (3), 807-13
DOI 10.1016/j.ijrobp.2004.04.018, PubMed 15465197

Sundstrøm S, Bremnes R, Aasebø U, Aamdal S, Hatlevoll R, Brunsvig P, Johannessen DC, Klepp O, Fayers PM, Kaasa S (2004)
Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial
J Clin Oncol, 22 (5), 801-10
DOI 10.1200/JCO.2004.06.123, PubMed 14990635

Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group (2004)
Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen)
Lung Cancer, 48 (2), 251-61
DOI 10.1016/j.lungcan.2004.10.016, PubMed 15829326

Publications 2003

Bremnes RM, Sundstrom S, Aasebo U, Kaasa S, Hatlevoll R, Aamdal S, Norwegian Lung Canc Study Grp (2003)
The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up
Lung Cancer, 39 (3), PII S0169-5002(02)00508-1-313

Bremnes RM, Sundstrom S, Aasebø U, Kaasa S, Hatlevoll R, Aamdal S, Norweigian Lung Cancer Study Group (2003)
The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up
Lung Cancer, 39 (3), 303-13
PubMed 12609569

Dueland S, Guren MG, Olsen DR, Poulsen JP, Magne Tveit K (2003)
Radiation therapy induced changes in male sex hormone levels in rectal cancer patients
Radiother Oncol, 68 (3), 249-53
DOI 10.1016/S0167-8140(03)00120-8, PubMed 13129632

Dueland S, Sauer T, Lund-Johansen F, Ostenstad B, Tveit KM (2003)
Epidermal growth factor receptor inhibition induces trichomegaly
Acta Oncol, 42 (4), 345-6
DOI 10.1080/02841860310006038, PubMed 12899508

Guren MG, Dueland S, Skovlund E, Fosså SD, Poulsen JP, Tveit KM (2003)
Quality of life during radiotherapy for rectal cancer
Eur J Cancer, 39 (5), 587-94
DOI 10.1016/S0959-8049(02)00741-4, PubMed 12628837

Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Håkansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G (2003)
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report
Eur J Cancer, 39 (1), 70-7
PubMed 12504661

Marchand M, Punt CJA, Aamdal S, Escudier B, Kruit WHJ, Keilholz U, Hakansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AMM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G (2003)
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report
Eur. J. Cancer, 39 (1), PII S0959-8049(02)00479-3-77

Publications 2002

Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S, Norwegian Lung Cancer Study Group (2002)
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up
J Clin Oncol, 20 (24), 4665-72
DOI 10.1200/JCO.2002.12.111, PubMed 12488411

Publications 2001

Bos AM, de Vries EG, Dombernovsky P, Aamdal S, Uges DR, Schrijvers D, Wanders J, Roelvink MW, Hanauske AR, Bortini S, Capriati A, Crea AE, Vermorken JB (2001)
Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours
Cancer Chemother Pharmacol, 48 (5), 361-9
DOI 10.1007/s002800100350, PubMed 11761453

Dueland S, Wist E, Løberg M, Iversen J (2001)
Cutaneous relapse of testicular embryonic carcinoma
J Urol, 165 (3), 909
DOI 10.1016/S0022-5347(05)66565-2, PubMed 11176507

Fodstad O, Faye R, Høifødt HK, Skovlund E, Aamdal S (2001)
Immunobead-based detection and characterization of circulating tumor cells in melanoma patients
Recent Results Cancer Res, 158, 40-50
PubMed 11092032

Guren MG, Wiig JN, Dueland S, Tveit KM, Fosså SD, Waehre H, Giercksky KE (2001)
Quality of life in patients with urinary diversion after operation for locally advanced rectal cancer
Eur J Surg Oncol, 27 (7), 645-51
DOI 10.1053/ejso.2001.1195, PubMed 11669593

Hovig E, Myklebost O, Aamdal S, Smeland EB (2001)
[Gene therapy in cancer]
Tidsskr Nor Laegeforen, 121 (4), 482-8
PubMed 11255868

Sudbø J, Warloe T, Aamdal S, Reith A, Bryne M (2001)
[Diagnosis and treatment of oral precancerous lesions]
Tidsskr Nor Laegeforen, 121 (26), 3066-71 (Retracted)
PubMed 11757442

Publications 2000

Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000)
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
J Clin Oncol, 18 (1), 158-66
DOI 10.1200/JCO.2000.18.1.158, PubMed 10623706

Pavlidis N, Aamdal S, Awada A, Calvert H, Fumoleau P, Sorio R, Punt C, Verweij J, van Oosterom A, Morant R, Wanders J, Hanauske AR (2000)
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)
Cancer Chemother Pharmacol, 46 (2), 167-71
DOI 10.1007/s002800000134, PubMed 10972487

Spitsen GM, Dueland S, Krisans SK, Slattery CJ, Miyake JH, Davis RA (2000)
In nonhepatic cells, cholesterol 7alpha-hydroxylase induces the expression of genes regulating cholesterol biosynthesis, efflux, and homeostasis
J Lipid Res, 41 (8), 1347-55
PubMed 10946023

Aamdal S, Lund B, Koier I, Houten M, Wanders J, Verweij J (2000)
Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG)
Cancer Chemother Pharmacol, 45 (1), 85-8
DOI 10.1007/PL00006748, PubMed 10647507

Publications 1998

Dueland S, Stenwig AE, Heilo A, Høie J, Ous S, Fosså SD (1998)
Treatment and outcome of patients with extragonadal germ cell tumours--the Norwegian Radium Hospital's experience 1979-94
Br J Cancer, 77 (2), 329-35
DOI 10.1038/bjc.1998.51, PubMed 9461006

Jungnelius U, Ringborg U, Aamdal S, Mattsson J, Stierner U, Ingvar C, Malmström P, Andersson R, Karlsson M, Willman K, Wist E, Bjelkengren G, Westberg R (1998)
Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial
Eur J Cancer, 34 (9), 1368-74
DOI 10.1016/S0959-8049(98)00068-9, PubMed 9849419

Semb KA, Aamdal S, Bohmann T, Lucas C, Gerard B (1998)
Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma
Melanoma Res, 8 (6), 565-72
DOI 10.1097/00008390-199812000-00012, PubMed 9918419

Semb KA, Aamdal S, Mette E, Ingvar C, Gullaksen N, Osmundsen K (1998)
Zilascorb(H-2), a low-toxicity protein synthesis inhibitor that exhibits signs of anticancer activity in malignant melanoma
Anti-Cancer Drugs, 9 (9), 797-802

Semb KA, Aamdal S, Mette E, Ingvar C, Gullaksen N, Osmundsen K (1998)
Zilascorb(2H), a low-toxicity protein synthesis inhibitor that exhibits signs of anticancer activity in malignant melanoma
Anticancer Drugs, 9 (9), 797-802
PubMed 9840726

Semb KA, Aamdal S, Oian P (1998)
Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment
J Clin Oncol, 16 (10), 3426-32
DOI 10.1200/JCO.1998.16.10.3426, PubMed 9779722

Publications 1997

Borge LM, Brunsvig PF, Ritland S, Stene-Larsen G, Hannisdal E (1997)
[The project Better Cancer Care in Buskerud]
Tidsskr Nor Laegeforen, 117 (15), 2170-3
PubMed 9235704

Dueland S, France D, Wang SL, Trawick JD, Davis RA (1997)
Cholesterol 7alpha-hydroxylase influences the expression of hepatic apoA-I in two inbred mouse strains displaying different susceptibilities to atherosclerosis and in hepatoma cells
J Lipid Res, 38 (7), 1445-53
PubMed 9254069

Semb KA, Fodstad O, Klem B, Bibow K, Osmundsen K, Aamdal S (1997)
Zilascorb(H-2), a new reversible protein synthesis inhibitor: Clinical study of an oral preparation
Anti-Cancer Drugs, 8 (3), 296-303

Semb KA, Fodstad O, Klem B, Bibow K, Osmundsen K, Aamdal S (1997)
Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation
Anticancer Drugs, 8 (3), 296-303
PubMed 9095337

Aamdal S, Bruntsch U, Kerger J, Verweij J, ten Bokkel Huinink W, Wanders J, Rastogi R, Franklin HR, Kaye SB (1997)
Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity
Cancer Chemother Pharmacol, 40 (5), 439-43
DOI 10.1007/s002800050683, PubMed 9272122

Publications 1996

Hanauske AR, Catimel G, Aamdal S, ten Bokkel Huinink W, Paridaens R, Pavlidis N, Kaye SB, te Velde A, Wanders J, Verweij J (1996)
Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group
Br J Cancer, 73 (3), 397-9
DOI 10.1038/bjc.1996.68, PubMed 8562349

Karlsson M, Jungnelius U, Aamdal S, Boeryd B, Carstensen J, Kågedal B, Westberg R, Wingren S (1996)
Correlation of DNA ploidy and S-phase fraction with chemotherapeutic response and survival in a randomized study of disseminated malignant melanoma
Int J Cancer, 65 (1), 1-5
DOI 10.1002/(SICI)1097-0215(19960103)65:1<1::AID-IJC1>3.0.CO;2-6, PubMed 8543385

McLeod HL, Graham MA, Aamdal S, Setanoians A, Groot Y, Lund B (1996)
Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group
Eur J Cancer, 32A (9), 1518-22
DOI 10.1016/0959-8049(96)00120-7, PubMed 8911111

McLeod HL, Murray LS, Wanders J, Setanoians A, Graham MA, Pavlidis N, Heinrich B, ten Bokkel Huinink WW, Wagener DJ, Aamdal S, Verweij J (1996)
Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups
Br J Cancer, 74 (12), 1944-8
DOI 10.1038/bjc.1996.657, PubMed 8980394

Semb KA, Aamdal S, Fosså SD, Oian P (1996)
Transcapillary forces of the subcutaneous tissue in patients treated with interleukin-2 and alpha-interferon: no capillary protein leak syndrome?
J Exp Ther Oncol, 1 (3), 155-61
PubMed 9414399

Trawick JD, Lewis KD, Dueland S, Moore GL, Simon FR, Davis RA (1996)
Rat hepatoma L35 cells, a liver-differentiated cell line, display resistance to bile acid repression of cholesterol 7 alpha-hydroxylase
J Lipid Res, 37 (3), 588-98
PubMed 8728321

Publications 1995

Fosså SD, Aamdal S, Naume B, Gallati H (1995)
Serum levels of cytokines and soluble cytokine receptors in patients with metastatic renal cell carcinoma or malignant melanoma receiving IL-2/interferon-alpha combination therapy
Acta Oncol, 34 (5), 599-603
DOI 10.3109/02841869509094034, PubMed 7546824

Verweij J, Catimel G, Sulkes A, Sternberg C, Wolff I, Aamdal S, van Hoesel Q (1995)
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group
Eur J Cancer, 31A Suppl 4, S21-4
DOI 10.1016/0959-8049(95)00362-M, PubMed 7577101

Publications 1994

Sessa C, Aamdal S, Wolff I, Eppelbaum R, Smyth JF, Sulkes A, Ten Bokkel Huinink W, Vermorken J, Wanders J, Franklin H (1994)
Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group
Ann Oncol, 5 (5), 471-2
DOI 10.1093/oxfordjournals.annonc.a058884, PubMed 8075055

Verweij J, Aamdal S, Schellens J, Koier I, Lund B (1994)
Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group
Oncol Res, 6 (10-11), 519-23
PubMed 7620220

Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger J, Schachter J, Wanders J, Franklin HR, Verweij J (1994)
Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group
Eur J Cancer, 30A (8), 1061-4
DOI 10.1016/0959-8049(94)90456-1, PubMed 7654429

Publications 1993

Dueland S, Drisko J, Graf L, Machleder D, Lusis AJ, Davis RA (1993)
Effect of dietary cholesterol and taurocholate on cholesterol 7 alpha-hydroxylase and hepatic LDL receptors in inbred mice
J Lipid Res, 34 (6), 923-31
PubMed 8354958

Gerard B, Aamdal S, Lee SM, Leyvraz S, Lucas C, D'Incalci M, Bizzari JP (1993)
Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma
Eur J Cancer, 29A (5), 711-9
DOI 10.1016/S0959-8049(05)80352-1, PubMed 8471329

Lundby B, Berg KJ, Lien HH, Aamdal S (1993)
A double blind study to evaluate the tolerability of gadodiamide injection and its effect on renal function in patients undergoing cerebral magnetic resonance imaging
Br J Radiol, 66 (790), 871-6
DOI 10.1259/0007-1285-66-790-871, PubMed 8220968

Publications 1992

Beiske K, Myklebust AT, Aamdal S, Langholm R, Jakobsen E, Fodstad O (1992)
Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods
Am J Pathol, 141 (3), 531-8
PubMed 1381558

Dueland S, Trawick JD, Nenseter MS, MacPhee AA, Davis RA (1992)
Expression of 7 alpha-hydroxylase in non-hepatic cells results in liver phenotypic resistance of the low density lipoprotein receptor to cholesterol repression
J Biol Chem, 267 (32), 22695-8
PubMed 1429619

Flørenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O (1992)
Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression
Cancer Res, 52 (21), 6088-91
PubMed 1356624

Thrift RN, Drisko J, Dueland S, Trawick JD, Davis RA (1992)
Translocation of apolipoprotein B across the endoplasmic reticulum is blocked in a nonhepatic cell line
Proc Natl Acad Sci U S A, 89 (19), 9161-5
PubMed 1409618

Wibe E, Hannisdal E, Paus E, Aamdal S (1992)
Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma
Eur J Cancer, 28A (10), 1692-5
DOI 10.1016/0959-8049(92)90070-I, PubMed 1389487

Aamdal S (1992)
Can ondansetron hydrochloride (Zofran) enhance the nephrotoxic potential of other drugs?
Ann Oncol, 3 (9), 774
DOI 10.1093/oxfordjournals.annonc.a058342, PubMed 1450070

Aamdal S, Gerard B, Bohman T, D'Incalci M (1992)
Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity
Eur J Cancer, 28 (2-3), 447-50
DOI 10.1016/S0959-8049(05)80074-7, PubMed 1591062

Publications 1991

Dueland S, Myhre K, Dueland AN, Saugstad OD (1991)
Increased plasma hypoxanthine values in humans during exposure to simulated altitude of 7,620 meters (25,000 feet)
Aviat Space Environ Med, 62 (11), 1044-9
PubMed 1741717

Dueland S, Nenseter MS, Drevon CA (1991)
Uptake and degradation of filamentous actin and vitamin D-binding protein in the rat
Biochem J, 274 ( Pt 1), 237-41
PubMed 2001239

Dueland S, Reichen J, Everson GT, Davis RA (1991)
Regulation of cholesterol and bile acid homoeostasis in bile-obstructed rats
Biochem J, 280 ( Pt 2), 373-7
PubMed 1747109

Leighton JK, Dueland S, Straka MS, Trawick J, Davis RA (1991)
Activation of the silent endogenous cholesterol-7-alpha-hydroxylase gene in rat hepatoma cells: a new complementation group having resistance to 25-hydroxycholesterol
Mol Cell Biol, 11 (4), 2049-56
PubMed 2005896

Myklebust AT, Beiske K, Pharo A, Davies CD, Aamdal S, Fodstad O (1991)
Selection of anti-SCLC antibodies for diagnosis of bone marrow metastasis
Br J Cancer Suppl, 14, 49-53
PubMed 1645572

Stoter G, Aamdal S, Rodenhuis S, Cleton FJ, Iacobelli S, Franks CR, Oskam R, Shiloni E (1991)
Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study
J Clin Oncol, 9 (9), 1687-91
DOI 10.1200/JCO.1991.9.9.1687, PubMed 1875225

Publications 1990

Brunsvig PF, Os I, Frederichsen P (1990)
[Hyponatremia. A retrospective study of occurrence, etiology and mortality]
Tidsskr Nor Laegeforen, 110 (18), 2367-9
PubMed 2218994

Dueland S, Blomhoff R, Pedersen JI (1990)
Uptake and degradation of vitamin D binding protein and vitamin D binding protein-actin complex in vivo in the rat
Biochem J, 267 (3), 721-5
PubMed 2339982

Straka MS, Junker LH, Zacarro L, Zogg DL, Dueland S, Everson GT, Davis RA (1990)
Substrate stimulation of 7 alpha-hydroxylase, an enzyme located in the cholesterol-poor endoplasmic reticulum
J Biol Chem, 265 (13), 7145-9
PubMed 2332427

Tefre T, Børresen AL, Aamdal S, Brøgger A (1990)
Studies of the L-myc DNA polymorphism and relation to metastasis in Norwegian lung cancer patients
Br J Cancer, 61 (6), 809-12
DOI 10.1038/bjc.1990.182, PubMed 1973618

Wibe E, Paus E, Aamdal S (1990)
Neuron specific enolase (NSE) in serum of patients with malignant melanoma
Cancer Lett, 52 (1), 29-31
DOI 10.1016/0304-3835(90)90073-7, PubMed 2354416

Publications 1989

Stoter G, Shiloni E, Aamdal S, Cleton FJ, Iacobelli S, Bijman JT, Palmer P, Franks CR, Rodenhuis S (1989)
Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study
Eur J Cancer Clin Oncol, 25 Suppl 3, S41-3
PubMed 2697578

Publications 1988

Fodstad O, Kjønniksen I, Aamdal S, Nesland JM, Boyd MR, Pihl A (1988)
Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells
Cancer Res, 48 (15), 4382-8
PubMed 3390834

Fodstad O, Aamdal S, McMenamin M, Nesland JM, Pihl A (1988)
A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOX
Int J Cancer, 41 (3), 442-9
DOI 10.1002/ijc.2910410322, PubMed 3346110

Aamdal S, Fodstad O, Pihl A (1988)
Sodium thiosulfate fails to increase the therapeutic index of intravenously administered cis-diamminedichloroplatinum (II) in mice bearing murine and human tumors
Cancer Chemother Pharmacol, 21 (2), 129-33
PubMed 3349560

Publications 1987

Brunsvig PF, Reikvam A, Nordgård S (1987)
[Protracted digitalis poisoning]
Tidsskr Nor Laegeforen, 107 (9), 843-4
PubMed 3590123

Gundersen S, Aamdal S, Fodstad O (1987)
Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease
Br J Cancer, 55 (4), 433-5
DOI 10.1038/bjc.1987.85, PubMed 3580266

Aamdal S, Fodstad O, Pihl A (1987)
Some procedures to reduce cis-platinum toxicity reduce antitumour activity
Cancer Treat Rev, 14 (3-4), 389-95
DOI 10.1016/0305-7372(87)90035-1, PubMed 3326670

Publications 1986

Aamdal S, Fodstad O, Kaalhus O, Pihl A (1986)
Chemosensitivity profiles of human cancers assessed by the 6-day SRC assay on serially xenografted tumors
Int J Cancer, 37 (4), 579-87
DOI 10.1002/ijc.2910370417, PubMed 3957463

Publications 1985

Albrechtsen D, Helgerud P, Rugstad HE, Dueland S (1985)
Very high concentration in intestinal lymph after oral, but not after intravenous, cyclosporine in the rat
Transplantation, 40 (2), 220-2
DOI 10.1097/00007890-198508000-00025, PubMed 4024244

Dueland S, Bouillon R, Van Baelen H, Pedersen JI, Helgerud P, Drevon CA (1985)
Binding protein for vitamin D and its metabolites in rat mesenteric lymph
Am J Physiol, 249 (1 Pt 1), E1-5
DOI 10.1152/ajpendo.1985.249.1.E1, PubMed 2990230

Fodstad O, Aamdal S, Pihl A, Boyd MR (1985)
Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas
Cancer Res, 45 (4), 1778-86
PubMed 3978640

Aamdal S, Fodstad O, Nesland JM, Pihl A (1985)
Characteristics of human tumour xenografts transplanted under the renal capsule of immunocompetent mice
Br J Cancer, 51 (3), 347-56
DOI 10.1038/bjc.1985.46, PubMed 3970811

Aamdal S, Fodstad O, Pihl A (1985)
The six-day subrenal capsule assay (SRCA) for testing the response of human tumours to anticancer agents. Validity and usefulness in cancer research and treatment
Ann Chir Gynaecol Suppl, 199, 51-9
PubMed 3864392

Aamdal S, Fodstad O, Pihl A (1985)
Methodological aspects of the 6-day subrenal capsule assay for measuring the response of human tumors to anticancer agents
Anticancer Res, 5 (4), 329-37
PubMed 4037730

Publications 1984

Blomhoff R, Helgerud P, Dueland S, Berg T, Pedersen JI, Norum KR, Drevon CA (1984)
Lymphatic absorption and transport of retinol and vitamin D-3 from rat intestine. Evidence for different pathways
Biochim Biophys Acta, 772 (2), 109-16
PubMed 6326820

Fodstad O, Kvalheim G, Godal A, Lotsberg J, Aamdal S, Høst H, Pihl A (1984)
Phase I study of the plant protein ricin
Cancer Res, 44 (2), 862-5
PubMed 6692385

Aamdal S, Børmer O, Jørgensen O, Høst H, Eliassen G, Kaalhus O, Pihl A (1984)
Estrogen receptors and long-term prognosis in breast cancer
Cancer, 53 (11), 2525-9
DOI 10.1002/1097-0142(19840601)53:11<2525::AID-CNCR2820531126>3.0.CO;2-8, PubMed 6713348

Aamdal S, Fodstad O, Kaalhus O, Pihl A (1984)
Reduced antineoplastic activity in mice of cisplatin administered with high salt concentration in the vehicle
J Natl Cancer Inst, 73 (3), 743-52
PubMed 6590919

Aamdal S, Fodstad O, Pihl A (1984)
Human tumor xenografts transplanted under the renal capsule of conventional mice. Growth rates and host immune response
Int J Cancer, 34 (5), 725-30
DOI 10.1002/ijc.2910340521, PubMed 6500747

Publications 1983

Dueland S, Helgerud P, Pedersen JI, Berg T, Drevon CA (1983)
Plasma clearance, transfer, and distribution of vitamin D3 from intestinal lymph
Am J Physiol, 245 (4), E326-31
DOI 10.1152/ajpendo.1983.245.4.E326, PubMed 6312805

Dueland S, Pedersen JI, Helgerud P, Drevon CA (1983)
Absorption, distribution, and transport of vitamin D3 and 25-hydroxyvitamin D3 in the rat
Am J Physiol, 245 (5 Pt 1), E463-7
DOI 10.1152/ajpendo.1983.245.5.E463, PubMed 6314821

Publications 1982

Davis RA, Helgerud P, Dueland S, Drevon CA (1982)
Evidence that reverse cholesterol transport occurs in vivo and requires lecithin-cholesterol acyltransferase
Biochim Biophys Acta, 689 (2), 410-4
PubMed 7115718

Dueland S, Pedersen JI, Drevon CA, Björkhem I (1982)
26-hydroxylation of 5 beta-cholestane-3 alpha,7 alpha,12 alpha-triol by isolated nonparenchymal cells and hepatocytes from rat liver
J Lipid Res, 23 (9), 1321-7
PubMed 7161561

Dueland S, Pedersen JI, Helgerud P, Drevon CA (1982)
Transport of vitamin D3 from rat intestine. Evidence for transfer of vitamin D3 from chylomicrons to alpha-globulins
J Biol Chem, 257 (1), 146-50
PubMed 6171567

Hansen CE, Dueland S, Drevon CA, Størmer FC (1982)
Metabolism of ochratoxin A by primary cultures of rat hepatocytes
Appl Environ Microbiol, 43 (6), 1267-71
PubMed 7103484

Publications 1981

Dueland S, Holmberg I, Berg T, Pedersen JI (1981)
Uptake and 25-hydroxylation of vitamin D3 by isolated rat liver cells
J Biol Chem, 256 (20), 10430-4
PubMed 6270111

 
Page visits: 6834